UK Biotech Has Plenty of Cash. So Why Won't Anyone Go Public?

That's the key detail. Deal count jumped 67% year-on-year, with 25 separate rounds in Q1 2026 compared to the prior year. Average deal sizes are smaller, but the money is reaching more startups at more stages. Think of it as the difference between one person buying the entire bar a round versus twenty people each buying their own drinks: the second scenario means a lot more people are actually drinking.

The UK also punches above its weight in European context. British biotechs captured 57% of all European biotech venture capital in Q1 2026. That's not a rounding error; that's dominance.

A Global Problem, Not Just a British One

Before we pile on London too much, it's worth noting that the IPO window worldwide is only cracked open, not flung wide. The U.S. saw at least 12 biotech IPOs in all of 2025. Early 2026 brought some encouraging signs (four major listings raised roughly $1 billion combined), but access remains restricted to companies with late-stage clinical data and clear paths to profitability.

The median U.S. biotech IPO size in Q1 2026 hit $287.5 million, more than double the 2025 figure. Translation: only the big kids get to play. Preclinical companies haven't successfully gone public since 2024. If you don't have meaningful clinical results, public investors don't want to hear from you.

Analysts predict 30 to 35 global biotech IPOs for the full year. That's a recovery from the bottom, sure, but it's a far cry from the 2021 boom when companies could practically IPO on a napkin sketch and a dream.

The Government Wants to Help (But Can It?)

The UK government launched its Life Sciences Sector Plan in July 2025, pledging over £2 billion in initial funding with ambitions to make Britain Europe's leading life sciences economy. The plan includes faster clinical trial setup (under 150 days), up to £520 million for manufacturing, and streamlined regulatory pathways through the MHRA.

Some of these moves are already creating ripple effects. British Patient Capital has committed £160 million to six UK life sciences venture funds and invested £89 million directly into 11 growth-stage companies. Pension funds are starting to participate too, a structural shift that could unlock enormous pools of patient capital. The British Growth Partnership Fund I hit a £200 million first close involving UK pension funds, marking real progress under the Mansion House Accord.

But policy alone can't fix a broken public market. When Merck pulled £1 billion in expansion plans from London in 2025, it sent a clear signal that government enthusiasm doesn't automatically translate into corporate confidence. And the UK still trails the U.S. and China significantly in total venture financing, despite leading within Europe.

What Comes Next

The optimists see a tipping point approaching. Some experts have predicted at least two London biotech listings in 2026, though nothing has materialized yet. The macro backdrop is improving: the Nasdaq hit all-time highs, investor sentiment is warming, and a UK-U.S. pharmaceutical trade deal has added tailwinds.

The pessimists (or realists, depending on your perspective) point out that the fundamental problem hasn't changed. Why would a UK biotech endure the limitations of AIM when Nasdaq offers a deeper pool and better valuations? Until London can offer something genuinely competitive, the best British biotechs will keep doing what Exscientia did five years ago: list in America.

The money is there. The science is there. The companies are there. What's missing is a public market that can match the ambition. Until that changes, the UK biotech story remains a tale of two halves: a thriving private ecosystem feeding into a public market that refuses to open its doors.

That champagne isn't going to pop itself.

The Kidney Drug That Wasn't Supposed to Get Approved

Filspari just became the first FDA-approved treatment for FSGS, a rare kidney disease that's been without an approved therapy forever. The twist? The pivotal trial technically missed its main goal. How Travere pulled off the approval anyway is a story worth reading.